Facebook Twitter

Anti-HIV drug trials go well, Salt Lake’s Myriad Genetics says

SHARE Anti-HIV drug trials go well, Salt Lake’s Myriad Genetics says

Salt Lake-based Myriad Genetics Inc. said Thursday that pre-clinical data on its lead anti-HIV compound has demonstrated strong anti-HIV activity without harming human cell survival.

The company said it hopes to file an investigational new drug application for human clinical trials with the U.S. Food and Drug Administration this fiscal year.

Myriad believes the drug, which prevents the virus from replicating and infecting other cells, holds the potential for an entirely new class of AIDS therapeutics.